Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition
about
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDCognitive enhancers for the treatment of ADHDLeveraging the cortical cholinergic system to enhance attentionDeficits in attentional control: cholinergic mechanisms and circuitry-based treatment approachesUnravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptorsSelectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brainCigarette Cravings, Impulsivity, and the BrainThe complicated relationship between attention deficit/hyperactivity disorder and substance use disordersStriatal cholinergic interneuron regulation and circuit effectsEnantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands.Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive DisordersEfficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover studyTargeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to dateNicotine increases impulsivity and decreases willingness to exert cognitive effort despite improving attention in "slacker" rats: insights into cholinergic regulation of cost/benefit decision makingPharmacological Characterisation of Nicotinic Acetylcholine Receptors Expressed in Human iPSC-Derived NeuronsnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine.Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neuronsPrefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signalingChemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsNovel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor.Modes and models of forebrain cholinergic neuromodulation of cognition.Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish.Do executive function deficits predict later substance use disorders among adolescents and young adults?Alzheimer's disease and age-related memory decline (preclinical)Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers.Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.Neurobiological impact of nicotinic acetylcholine receptor agonists: an activation likelihood estimation meta-analysis of pharmacologic neuroimaging studiesNonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake.Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3.Nicotinic receptors in neurodegeneration.Significant association between rare IPO11-HTR1A variants and attention deficit hyperactivity disorder in CaucasiansCigarette smoking associated with attention deficit hyperactivity disorder.Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trialsCrystal structure of a human neuronal nAChR extracellular domain in pentameric assembly: Ligand-bound α2 homopentamerNicotine self-medication of cognitive-attentional processing.Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.
P2860
Q21260332-4F15A6AD-358B-4EDF-92B7-11E3B7C83704Q22251235-5A73C330-AAF4-4581-AB30-76239BC59620Q24598925-46D76339-CD26-4A16-812C-0467A47D40E5Q24629686-4E974FE1-4F9E-4F15-9AA3-CF423C55FE5CQ24634426-DF6AB620-D725-4DC1-9960-57389A1F5874Q24645468-7655F33F-E8BE-4A79-97A4-8A0FA76C01BEQ26781531-F46381CC-16E2-4785-BE24-73A92630E77CQ26851607-27FF5CD5-CA2C-4107-9038-A76F9436F8C5Q26863113-2C6C52E6-168E-4516-A19B-EB179D54C1B7Q27335322-70CD6951-F0F2-4218-8E53-A5478FB8FA6CQ27693356-14A9E283-FCD0-429B-8517-644A55E191AFQ28076907-B9E85A6A-668D-4DFF-9523-3D5086206474Q28243031-8E10D2A3-DCB8-46EE-B78B-321E916947F3Q28250463-5E333BD0-305F-4E76-A4D6-160A3CC4237DQ28544471-F05DA4A3-2023-472B-B03B-6BF38B1E3F41Q28546676-D82B3FF9-2147-4171-BF2F-5ECB292F402AQ30362464-4B6D3DB4-0F78-4DF6-9CF5-E57A845AEC13Q30445192-2BECDD1D-BFDC-4D5C-933B-3F95B346A55FQ30467200-2F177A22-DE89-4057-9D12-1EBAF37F8B26Q33830056-986C94F6-D06A-4F0E-8261-755A9B6D791FQ34215376-3815D085-2EE2-4337-A107-92D4117CB9C1Q34220004-2E0C7A07-E4D9-4FFC-9D50-7F615F465C40Q34348499-F6331540-3995-4C77-A929-21244BE178B8Q34355481-36DFDC29-1437-4253-A4FB-FD06F396A5F5Q34390062-DF29CF4B-C7CF-4CE3-AA01-1EF1A0271317Q34766531-97D00C26-089B-4D1A-B187-51CB05299B74Q35041190-978DF1A9-7B46-49EB-A814-F378DE01B68EQ35151922-825F9AA9-D5E7-471C-A373-BF52D8DB301CQ35588731-63B17937-1371-4646-A234-8638C2221BF7Q35738694-0E202D9E-4BFC-4900-903C-AA095801C977Q35828730-057F7EE5-7CC6-471D-AD83-B8CB979B9F95Q36326822-75718B43-85CA-4D7B-8088-40A5B7F21180Q36695755-478883EA-2F01-4EA6-9C50-C7DDDE3091CCQ36828916-63F79860-D280-41F3-A3FC-5AB17758BEDBQ36853488-1EEA8925-D574-4FDC-B927-7BD7236A4B84Q36919610-F923B718-62A3-415B-94B4-449CA3E346BCQ37134091-23A44C1C-1832-4290-9F4F-8D464226A122Q37213682-CA1C1D4B-1B20-4A23-BFEA-1DB4FE41F5E8Q37294509-FF0A0D14-E3D9-4BC9-B9EA-E4B7A4A48786Q37355700-F0F75AD8-45EF-4E87-B485-1ABAEF5E9030
P2860
Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@ast
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@en
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@nl
type
label
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@ast
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@en
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@nl
prefLabel
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@ast
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@en
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@nl
P2860
P1476
Neuronal nicotinic receptor ag ...... y disorder: focus on cognition
@en
P2093
Michael W Decker
Timothy E Wilens
P2860
P304
P356
10.1016/J.BCP.2007.07.002
P407
P577
2007-10-15T00:00:00Z